TransCode Therapeutics (RNAZ) Investor presentation summary

Strategic vision and platforms

• Focused on transforming advanced cancer care through three platforms: RNA-targeted therapeutics, vaccine immunotherapies, and immuno-oncolytic agents.

• Pipeline includes TTX-MC138 (RNA therapeutic), Seviprotimut-L (cancer vaccine), and UIO-524 (oncolytic virus).

• Emphasis on targeting metastatic disease and enhancing immune response.

• Harvard and Massachusetts General Hospital faculty founders.

• $100 million invested since IPO, no long-term debt.

Clinical pipeline and development

• TTX-MC138 is in Phase 2a for colorectal cancer minimal residual disease, with prior Phase 1a showing 64% disease stabilization and strong tolerability.

• Seviprotimut-L completed a Phase 3 trial in melanoma, showing trends toward improved recurrence-free and overall survival.

• UIO-524, an engineered oncolytic virus, demonstrated significant preclinical activity in tumor models and is advancing toward IND.

• Multiple assets have received FDA orphan drug status.

• Near-term catalysts include Phase 2a enrollment completion and preliminary data for TTX-MC138.

Clinical results and safety

• TTX-MC138 Phase 1a met primary safety endpoint with no dose-limiting toxicities up to 4.8 mg/kg.

• Most adverse events were mild to moderate; Grade 3 or higher events were rare and not clinically significant.

• Durable disease stabilization observed in 64% of evaluable metastatic patients.

• Pharmacokinetic profile consistent with preclinical data, supporting tumor uptake.

• Case study in metastatic thyroid cancer showed biomarker reduction and ongoing stable disease.